Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,800 matching trials from the live ClinicalTrials.gov search.
Conditions
Drug Extravasation, Kidney Cancer
Interventions
aldesleukin, Biomed 101
Biological · Drug
Lead sponsor
BioMedicines
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Kidney Cancer
Interventions
filgrastim, cyclosporine, pentostatin, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Kidney Cancer
Interventions
aldesleukin, recombinant interferon alfa, fluorouracil, isotretinoin, surgical procedure
Biological · Drug · Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
Interventions
Belzutifan, Cabozantinib
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 5 more
Conditions
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Any T-cell Malignancy, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma, Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Burkett's Lymphoma, Primary Lymphoma of the Central Nervous System
Interventions
CDX-1127
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
Conditions
Clear Cell Sarcoma of the Kidney, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Rhabdoid Tumor of the Kidney, Stage I Wilms Tumor, Stage II Wilms Tumor, Stage III Wilms Tumor, Stage IV Wilms Tumor, Stage V Wilms Tumor
Interventions
DNA methylation analysis, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 16 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Monrovia, California
Completed Phase 2 Interventional Results available

Survivorship Promotion In Reducing IGF-1 Trial

NCT02431676
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions
Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Kidney Cancer, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma
Interventions
filgrastim, allogeneic bone marrow transplantation
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
2
States / cities
Nashville, Tennessee • Seattle, Washington
Conditions
Kidney Cancer
Interventions
lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more
Conditions
Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Renal Cell Carcinoma, Melanoma
Interventions
GVAX
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Urothelial Cancer, Bladder Cancer, Genitourinary Cancer, Urogenital Neoplasms, Urogenital Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2042
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
LY2510924, Sunitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
21
States / cities
Scottsdale, Arizona • Norwich, Connecticut • Newark, Delaware + 18 more
Conditions
Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions
XmAb®22841, Pembrolizumab (Keytruda®)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Encinitas, California • La Jolla, California • Los Angeles, California + 15 more
Terminated No phase listed Observational Accepts healthy volunteers

Effect of PARP Inhibitors on Glomerular Filtration Rate

NCT04367467
Conditions
Solid Tumor, Ovarian Cancer, Breast Cancer
Interventions
Kidney Function Test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Renal Cell Carcinoma
Interventions
Hydroxychloroquine, IL-2
Drug
Lead sponsor
Leonard Appleman
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
7
States / cities
Maywood, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 4 more
Conditions
Carcinoma, Renal Cell, Prostatic Neoplasms
Interventions
FK228 (romidepsin)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Duarte, California • Gainesville, Florida • Chicago, Illinois + 1 more
Conditions
Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
Interventions
Avelumab, Sunitinib
Drug
Lead sponsor
Guru Sonpavde
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Low Grade Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Hodgkin Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Hodgkin Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Soft Tissue Sarcoma, Rhabdoid Tumor, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Wilms Tumor
Interventions
Tazemetostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 91 more
Conditions
Kidney Cancer
Interventions
sunitinib malate, gene expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Harry Drabkin
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Pleuropulmonary Blastoma, Cystic Nephroma, Sertoli-Leydig Cell Tumor of Ovary, Medulloepithelioma, Embryonal Rhabdomyosarcoma of Cervix, Goiter, Sarcoma, Pineoblastoma, Pituitary Tumors, Wilms Tumor
Interventions
Not listed
Lead sponsor
Ashley Hill
Other
Eligibility
1 Day to 95 Years
Enrollment
1,247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Aerosolized Aldesleukin, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Brain Metastases
Interventions
Whole brain radiation, Stereotactic radiation (SRS)
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Active, not recruiting No phase listed Observational

Impact of COVID-19 on GU Disease

NCT04761107
Conditions
COVID-19 Infection, Genitourinary Cancer, Benign Urologic Conditions
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
40 Years and older
Enrollment
15,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York